Decibel Therapeutics, Inc.


Regeneron is dedicated to moving science to medicine, aiming to transform the lives of people with serious diseases through innovative biopharmaceutical solutions. The company emphasizes pioneering a new era in biopharmaceutical innovation, leveraging cutting-edge science and technology to develop life-changing medicines. Regeneron is committed to responsible business practices, fostering scientific talent, and making a significant impact in cancer research, genetics, immunology, and other medical fields. Their efforts include extensive research, technological innovation, collaborations, and a focus on genetic medicines, antibody technologies, personalized treatments, and addressing global health challenges.

Industries

biotechnology
medical-device
therapeutics

Nr. of Employees

medium (51-250)

Decibel Therapeutics, Inc.

Cambridge, Massachusetts, United States, North America


Products

Biologics and Genetic Medicines

Innovative biologic and genetic medicines for serious diseases.

Antibody Technologies

Development of monoclonal, bispecific, and other antibody-based therapies.

Gene Editing and Cell Therapies

Advanced therapies including gene editing and cell-based treatments.

Personalized Medicine Approaches

Tailoring treatments based on genetic and molecular profiles.


Services

Research and Development

Regeneron invests heavily in research and development to discover new medicines and therapies.

Manufacturing

The company manufactures investigational and approved medicines with high quality and efficiency.

Genetic and Genomic Research

Utilizing large-scale human genomics research to understand genetic drivers of health and disease.

Clinical Trials

Conducting clinical trials to test the safety and efficacy of new medicines.

Collaborations and Partnerships

Partnering with academic institutions, biotech, and other organizations to accelerate innovation.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.